Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi has entered into an agreement to acquire Pluromed, a medical device company based in Woburn, Massachusetts, US.
Subscribe to our email newsletter
Sanofi will commercialize Pluromed’s LeGoo, a gel indicated for temporary endovascular occlusion of blood vessels during surgical procedures.
LeGoo is a FDA approved and CE marked product.
This acquisition is subject to customary closing conditions.
Pluromed has developed Rapid Transition Polymers (RTP), a polymer technology, opening up the use of injectable plugs to improve the safety, efficacy and economics of medical interventions.
Sanofi Biosurgery senior vice president and general manager Alison Lawton said LeGoo is a breakthrough technology with the potential to change the paradigm of vascular and cardiovascular surgical procedures, by providing fast, temporary control of blood flow while avoiding vessel trauma associated with standard of care.